Operating Cash Flow
Alnylam Pharmaceuticals Operating Cash Flow decreased by 56.9% to $70.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 158.6%, from -$120.31M to $70.50M. Over 3 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a -6.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Consistently high operating cash flow indicates a healthy, self-sustaining business capable of funding its own growth and returning capital to shareholders.
Detailed definition
Net cash from operating activities measures the total amount of cash generated by a company's core business operations....
Peer comparison
Investors often compare this to capital expenditures to calculate Free Cash Flow, a primary valuation metric for mature tech giants.
net_cash_from_operatingHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$121.86M | -$134.04M | -$150.14M | -$171.19M | -$122.82M | -$115.28M | -$131.98M | -$166.48M | -$58.99M | $359.41M | -$81.52M | $124.16M | $43.71M | -$94.66M | -$120.31M | $155.73M | $325.11M | $163.56M | $70.50M |
| QoQ Change | — | -10.0% | -12.0% | -14.0% | +28.3% | +6.1% | -14.5% | -26.1% | +64.6% | +709.3% | -122.7% | +252.3% | -64.8% | -316.6% | -27.1% | +229.4% | +108.8% | -49.7% | -56.9% |
| YoY Change | — | — | — | — | -0.8% | +14.0% | +12.1% | +2.8% | +52.0% | +411.8% | +51.0% | +310.5% | -87.8% | — | -47.6% | +25.4% | +643.8% | +272.8% | +158.6% |
Operating Cash Flow at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's operating cash flow?
- Alnylam Pharmaceuticals (ALNY) reported operating cash flow of $70.50M in Q1 2026.
- How has Alnylam Pharmaceuticals's operating cash flow changed year-over-year?
- Alnylam Pharmaceuticals's operating cash flow increased by 158.6% year-over-year, from -$120.31M to $70.50M.
- What is the long-term trend for Alnylam Pharmaceuticals's operating cash flow?
- Over 3 years (2021 to 2025), Alnylam Pharmaceuticals's operating cash flow has grown at a -6.5% compound annual growth rate (CAGR), from -$641.69M to $524.08M.
- What does operating cash flow mean?
- The actual amount of cash a company brings in from its day-to-day business activities.